MarketPulse

cancer therapies

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Ascentage Pharma Group International

Ascentage Pharma Sets March 25 Earnings Call for 2025 Full-Year Results

Ascentage Pharma will report 2025 full-year unaudited results on March 25, 2026, with dual-language investor webcasts highlighting performance of its approved cancer therapies and clinical pipeline progress.
AAPGfinancial resultsclinical trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Cuts Nuvalent Position by $84M Despite Strong Stock Performance

Commodore Capital cuts $84M Nuvalent stake to 3.68% despite 29% stock gains. Biotech firm awaits September PDUFA decision for lead drug candidate.
RLAYNUVLFDA approvalclinical trials